c-kit Point mutation in patients with myeloproliferative disorders. - Wikidata - awgldk - TriplyDB

c-kit Point mutation in patients with myeloproliferative disorders.

c-kit Point mutation in patients with myeloproliferative disorders.

http://www.wikidata.org/entity/Q41486079

about

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells Effects of mutant c-Kit in early myeloid cells.Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.Stem cell factor and chronic myeloid leukemia CD34+ cells.Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis.Cellular signalling pathways: new targets in leukaemia therapy.Class III receptor tyrosine kinases: role in leukaemogenesis.Receptor tyrosine kinase mutations in myeloid neoplasms.Tyrosine kinase inhibitors as cancer therapy.Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.Normal and oncogenic forms of the receptor tyrosine kinase kit.Idiopathic myelofibrosis: pathogenesis to treatment.Beginning of personalized medicine in Panama: Molecular and pathological characteristics of gastrointestinal stromal tumors from archival paraffin-embedded tissue.The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.Effects of mutant c-kit in early myeloid cells.

P2860

Q26740953-99C56FB1-C7C3-4745-B404-0BC37DA0415A Q33735183-E8E29000-D6BF-483A-BB90-CFA1F8F50420 Q33753094-ECC4EC42-134E-4ACF-82D8-183E32EE8E16 Q33929798-EE3425A5-7289-499C-B143-1C09647C30AE Q34176633-AADDB50F-2F87-4C23-80E1-57FF9A2D93EF Q34527660-A0334BE4-54FA-49D6-B0A3-772C2804C08E Q34557003-FC9F1499-827B-465A-9DA7-E4B1775474A0 Q34655403-33C599BA-EE02-44F5-B3F9-747EB2545244 Q35589206-5439416C-C6BB-4066-8D3D-73B61AA5A975 Q35771147-5C3C290B-28A9-4E7E-9931-088A0F9FDDC8 Q35996350-ED485BF1-79D7-4B10-B1D8-5E38B7200891 Q36396209-92AB9DB4-EB44-4CAF-99BE-CABE578FD127 Q38401861-198F072C-B86E-428D-B0F1-827007404718 Q40390447-ED482B4B-C299-4B5C-A025-B25AE01AA875 Q53412286-3CAE6C24-1639-457F-AC69-0B0204883B66

P2860

c-kit Point mutation in patients with myeloproliferative disorders.

http://www.wikidata.org/entity/Q41486079

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

1997年论文

@zh

1997年论文

@zh-cn

name

c-kit Point mutation in patients with myeloproliferative disorders.

@en

type

label

c-kit Point mutation in patients with myeloproliferative disorders.

@en

prefLabel

c-kit Point mutation in patients with myeloproliferative disorders.

@en

P1433

Q41486079-0135EC0D-9319-401D-9AA9-07B83FA7F3C3

P1476

Q41486079-02612BFA-12D7-4F98-A8F0-360EBEB5ED49

P2093

Q41486079-43C92A4F-EC30-4AC3-9281-7ADC244B697A

Q41486079-52B2AD53-686C-458B-A30C-58046B9DF67E

Q41486079-632C3315-9134-4E49-B696-CB162A7699EE

Q41486079-BFE8729B-3C5B-4902-B3C1-3B512AD9869A

P2860

Q41486079-08C2C27D-3BCD-456C-B461-6062F7339473

Q41486079-11B3D681-D486-4073-89EB-4ACBDD89EF80

Q41486079-1EFBE6E1-0A2F-42AF-9EAE-B1120B627916

Q41486079-581850D3-F23C-4E75-A798-BD864C625550

Q41486079-5D13CFC1-F6F9-43A1-96AD-C2C78CAB0381

Q41486079-860AE65F-C971-4BB8-A8FB-11369AB5387C

Q41486079-A574397E-5DB4-449C-A184-967994B75FE1

Q41486079-B7B118AA-8D49-4BA5-B15C-0C514ABA312C

Q41486079-C7BB378A-609A-4243-81F0-9499952C0358

Q41486079-C854CEBC-78F4-4D78-B034-0988C81A1744

P304

Q41486079-B40BB405-3B1B-4F45-AB07-2FD348D5B501

P31

Q41486079-D67BB5A7-3596-47D5-94AD-1963A0B32591

P356

Q41486079-6B418EEF-A106-4F5C-90C3-3646862FF148

P433

Q41486079-3B7F2585-B549-49CF-AC76-F881660C4B86

P478

Q41486079-76EFABDE-671C-4C10-B318-5CCF2BF08300

P577

Q41486079-E7D1AAD0-D2BC-4DDD-8D31-2D92CED0C610

P698

Q41486079-0779EC9F-35BF-4AE0-809B-B19580F7F19A

P356

10428199709114167

P1433

Leukemia & Lymphoma

P1476

c-kit Point mutation in patients with myeloproliferative disorders.

@en

P2093

Hyodo H

http://www.w3.org/2001/XMLSchema#string

Katoh O

http://www.w3.org/2001/XMLSchema#string

Kimura A

http://www.w3.org/2001/XMLSchema#string

Nakata Y

http://www.w3.org/2001/XMLSchema#string

P2860

FMS mutations in myelodysplastic, leukemic, and normal subjects

Oncogenes and signal transduction

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

c-KIT expression enhances the leukemogenic potential of 32D cells

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.

In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.

Interspecies molecular chimeras of kit help define the binding site of the stem cell factor.

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family.

P304

281-287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428199709114167

http://www.w3.org/2001/XMLSchema#string

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

1997-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9168438

http://www.w3.org/2001/XMLSchema#string